Rigel Pharmaceuticals Inc. (New) Stock Prediction
AI-powered sentiment analysis and prediction trends for RIGL, updated each market day.
RIGL AI Sentiment
AI sees no strong directional signal for Rigel Pharmaceuticals Inc. (New) stock over the next 10 market days.
Prediction date: Sept. 23, 2026
Exact scores are in the SharePreds app
The precise prediction score for this stock, with buy and sell targets and a stop loss, updated every market day.
About Rigel Pharmaceuticals Inc. (New)
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
Sector
Exchange
Market Cap
$856,471,764
Cap Tier
Employees
174
Headquarters
SOUTH SAN FRANCISCO, CA
Listed Since
Nov. 29, 2000
Website
RIGL Sentiment Trend: Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
RIGL Volatility
Rigel Pharmaceuticals Inc. (New) has shown moderate price volatility over the last 5 trading days. Moderate volatility indicates normal market activity with typical price fluctuations.
